Loading publications…
The last 5 uploaded publications
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo (2022). Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular and Interventional Radiology, 45(4), pp. 405-412, DOI: 10.1007/s00270-021-03031-9.
Article145 days agoTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin, Jinfang Zheng, Sadahisa Ogasawara, Ji Hoon Kim, Haitao Zhao, Chuan Li, David C. Madoff, R. Mark Ghobrial, Tomokazu Kawaoka, René Gérolami, Masafumi Ikeda, Hiromitsu Kumada, Anthony B. El-Khoueiry, Arndt Vogel, Xiang Peng, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Josep M. Llovet (2025). Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet, 405(10474), pp. 203-215, DOI: 10.1016/s0140-6736(24)02575-3.
Article145 days agoP-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Sadahisa Ogasawara, Josep M. Llovet, Anthony B. El-Khoueiry, Arndt Vogel, David C. Madoff, Richard S. Finn, Zheng Ren, Kush Modi, J. Li, A.B. Siegel, Leonid Dubrovsky, Masatoshi Kudo (2020). P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Annals of Oncology, 31, pp. S124-S125, DOI: 10.1016/j.annonc.2020.04.189.
Article145 days agoLEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
Anthony B. El-Khoueiry, Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo (2022). LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 40(4_suppl), pp. TPS494-TPS494, DOI: 10.1200/jco.2022.40.4_suppl.tps494.
Article145 days ago1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Josep M. Llovet, Anthony B. El-Khoueiry, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zheng Ren, Kalgi Mody, J. Jing Li, A.B. Siegel, Leonid Dubrovsky, Masatoshi Kudo (2020). 1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals of Oncology, 31, pp. S702-S703, DOI: 10.1016/j.annonc.2020.08.1132.
Article145 days ago